Spine SABR

Name No. For Patients with Purpose
Spine SABR 20-03

oligometastatic disease (OMD) or oligoprogressive disease (OPD) solid tumour spine metastases

The Spine SABR (CTRIAL-IE 20-03) study has been designed to determine the maximum tolerated dose of stereotactic radiotherapy, to the spine, delivered in two fractions with a simultaneous integrated boost technique, for patients with oligometastatic or oligoprogressive spine disease.


Serum Protein Markers for Glioma

Name No. For Patients with Purpose
Serum Protein Markers for Glioma 08-13

Brain cancer (glioma).

The purpose of this trials is to investigate proteins and genes in brain tumours.